Close Menu

legal settlement

Genetic Technologies granted a non-exclusive license to Orchid Cellmark for a number of patents covering non-coding analysis, gene mapping, and internal standards.

The suit was filed in early November and accused PacBio of luring away at least 15 of Affymetrix's former employees.

The offer was extended to Dec. 16, so investors can consider disclosures in an amended SEC filing related to a settlement with shareholders.

Proteome Sciences had sued Sanofi-Aventis for breach of contract and statutory obligations in connection to a sales and transfer agreement which concerned a share and a limited partnership interest in Xzillion Proteomics.

The firm also raised around $1.7 million through a warrant conversion tied to a 2007 private placement.

The settlement ends a dispute over distribution rights to two DxS assays, with both firms having the right to distribute the products.

The EraGen license comes a couple of days after Gen-Probe took a license to the same non-coding patents.

Sequenom agreed to pay shareholders $14 million to settle a class action suit filed months after the firm's stock plummeted in the wake of an announcement regarding the mishandling of data on the firm's SEQureDx test.

Gen-Probe is one of several firms that were sued by Genetic Technologies in February for alleged infringement of a patent covering methods of analyzing non-coding DNA sequences.

The settlement will provide Celera with at least $7 million from the defendants in the litigation, and sets certain prohibitions, such as the soliciting or hiring of Berkeley HeartLab employees.

Pages

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.